2025 Is Make Or Break For Ginkgo Bioworks

Ginkgo Bioworks (NYSE: DNA ) remains focused on reducing cash burn and made significant progress in this area in the fourth quarter of 2024. While this is a positive, Ginkgo lacks direction, and its newer Cell Engineering offerings have demonstrated limitedRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by ident ...